Doffe, Flora
Carbonnier, Vincent
Tissier, Manon
Leroy, Bernard
Martins, Isabelle
Mattsson, Johanna S. M.
Micke, Patrick
Pavlova, Sarka
Pospisilova, Sarka
Smardova, Jana
Joerger, Andreas C.
Wiman, Klas G. http://orcid.org/0000-0002-7113-524X
Kroemer, Guido
Soussi, Thierry http://orcid.org/0000-0001-8184-3293
Funding for this research was provided by:
Radiumhemmets Forskningsfonder (-)
Article History
Received: 24 March 2020
Revised: 3 November 2020
Accepted: 4 November 2020
First Online: 30 November 2020
Compliance with ethical standards
:
: KGW is a cofounder and a shareholder of Aprea Therapeutics AB, a company that develops p53-based cancer therapies including APR-246. KGW is a member of its Clinical Advisory Board and has received salary and research funding from Aprea Therapeutics AB.